Pharmacovigilance and Drug Safety Software Market ReportPosted by Ryan Shaw on September 25th, 2019 The global Pharmacovigilance And Drug Safety Software Market size is expected to reach USD 207.7 million by 2024, according to a new report by Grand View Research, Inc., presenting a CAGR of 6.5% during the forecast period. Increasing number of adverse drug reactions (ADR) is a key factor for market growth. ADR imposes a significant burden on research organizations and companies. To curb this problem, pharmaceutical companies are opting for contract outsourcing of these services. Manufacturers are now striving to identify various ways of cost reduction and minimizing operational expenses by gradually shifting from being fully integrated pharmaceutical companies to sharing costs by collaborating with service providers. Outsourcing helps increase internal resource flexibility, improves timelines, and results in better outcomes in short as well as long terms. Outsourcing also helps achieve better pharmacovigilance (PV) through regulatory compliance, higher quality, better productivity, and improved strategic outcomes. PV service providers, in an attempt to ensure sustainability, are providing customized and end-to-end solutions to meet consumer needs. These firms are also incorporating integrated technologies such as electronic data capture and hosting of PV warehousing for aggregating cross industry data for benefit risk evaluation. Furthermore, the fact that service providers are now operating via a flexible and variable pricing structure and achieving operational excellence through constant product updates is expected to boost usage rates over the forecast period. Related Reading @ Pharmacovigilance Software Market – Preventing Adverse Drug Reactions Further key findings from the report suggest:
Like it? Share it!More by this author |